Sexually transmitted diseases, 1986; 13 (2) doi:
Sample size: 23
Abstract: Tetracyclines are the drugs of choice for treatment of Chlamydia trachomatis infection, but alternative antimicrobial agents are needed. Clindamycin has moderate in-vitro activity against C. trachomatis. In this study clindamycin (600 mg orally three times daily for seven days) was given to 76 men with nongonococcal urethritis. Initial microbiologic and clinical responses were significantly better in men from whom C. trachomatis was initially isolated, compared with men from whom Ureaplasma urealyticum was initially isolated, but by 42 +/- 7 days after initiation of treatment, persistence or recurrence of urethritis had occurred in 39% of men with either organism initially isolated. C. trachomatis was ultimately reisolated at follow-up evaluation from seven of 23 men who initially had had positive cultures for C. trachomatis. There was no apparent relationship between the in-vitro susceptibility of C. trachomatis and the ultimate response. These results indicate that clindamycin cannot be relied upon to eradicate C. trachomatis from men with urethritis.
The top research papers for the subject are placed on the map. Studies form clusters based on semantic relation.
Size of the point represents relevance of the paper.
You can pan and zoom the graph using mouse and mouse wheel.
Right click on the paper to:
Left click on keyword to add it to search.
Sign up to create your own map!
Explore the real nature of Life Sciences.
The first truly systematic Review of scientific literature and global Trends in Science.